Literature DB >> 31263038

Tim-4 Inhibits NLRP3 Inflammasome via the LKB1/AMPKα Pathway in Macrophages.

Wen Liu1, Fuxiang Bai2, Hongxing Wang1, Yan Liang1, Xianhong Du1, Cui Liu3, Dejian Cai4, Jiali Peng1, Guangming Zhong5, Xiaohong Liang1, Chunhong Ma1, Lifen Gao6.   

Abstract

Nonalcoholic fatty liver disease (NAFLD), characterized by excessive inflammation and lipid deposition, is one of the most common metabolic liver diseases. The expression of NLRP3 inflammasome in macrophages is significantly increased in NAFLD, and its activation aggravates NAFLD greatly. Tim-4, as the phosphatidylserine (PS) receptor, is expressed highly in macrophages, and macrophage Tim-4 inhibits inflammation under various conditions of immune activation. However, the precise role of Tim-4 in NLRP3 inflammasome regulation and NAFLD pathogenesis remains completely unknown. Using NAFLD mice models, we confirmed that the expression of Tim-4 was increased in liver tissues by Western blot, real-time PCR, immunohistochemistry, and immunofluorescence, especially higher expression in liver macrophages, and Tim-4 knockout mice displayed more severe liver inflammation and hepatic steatosis than controls in NAFLD mice model. In vitro, we found that Tim-4 could inhibit NLRP3 inflammasome activation, and the inhibition was dependent on PS binding domain in the IgV domain. Mechanistically, Tim-4 induced the degradation of NLRP3 inflammasome components through activating AMPKα-mediated autophagy. Specifically, Tim-4 promoted AMPKα phosphorylation by interacting with LKB1 and AMPKα. In addition, PS binding motif was responsible for Tim-4-mediated AMPKα and LKB1 interaction. In conclusion, NAFLD microenvironments upregulate Tim-4 expression in macrophages, and elevated Tim-4, in turn, suppresses NLRP3 inflammasome activation by activating LKB1/AMPKα-mediated autophagy, thereby ameliorating the release of IL-1β and IL-18. Collectively, this study unveils the novel function of Tim-4 in suppressing NLRP3 inflammasome, which would shed new lights on intervention of NAFLD or inflammatory liver diseases by targeting Tim-4.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Year:  2019        PMID: 31263038     DOI: 10.4049/jimmunol.1900117

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Lycopene alleviates hepatic ischemia reperfusion injury via the Nrf2/HO-1 pathway mediated NLRP3 inflammasome inhibition in Kupffer cells.

Authors:  Rong Xue; Jiannan Qiu; Song Wei; Mu Liu; Qi Wang; Peng Wang; Bowen Sha; Hao Wang; Yong Shi; Jinren Zhou; Jianhua Rao; Ling Lu
Journal:  Ann Transl Med       Date:  2021-04

Review 2.  Tim-4 in Health and Disease: Friend or Foe?

Authors:  Wen Liu; Liyun Xu; Xiaohong Liang; Xiaojun Liu; Yangbing Zhao; Chunhong Ma; Lifen Gao
Journal:  Front Immunol       Date:  2020-04-02       Impact factor: 7.561

Review 3.  LKB1 Regulates Vascular Macrophage Functions in Atherosclerosis.

Authors:  Xuewen Wang; Ziwei Liang; Hong Xiang; Yanqiu Li; Shuhua Chen; Hongwei Lu
Journal:  Front Pharmacol       Date:  2021-12-15       Impact factor: 5.810

Review 4.  Efferocytosis in multisystem diseases (Review).

Authors:  Yifan Zhang; Yiru Wang; Jie Ding; Ping Liu
Journal:  Mol Med Rep       Date:  2021-11-15       Impact factor: 2.952

5.  A Novel Pyrazolo[3,4-d]pyrimidine Induces Heme Oxygenase-1 and Exerts Anti-Inflammatory and Neuroprotective Effects.

Authors:  Ji Ae Lee; Young-Won Kwon; Hye Ri Kim; Nari Shin; Hyo Jin Son; Chan Seong Cheong; Dong Jin Kim; Onyou Hwang
Journal:  Mol Cells       Date:  2022-03-31       Impact factor: 5.034

6.  Modern Beijing sublineage of Mycobacterium tuberculosis shift macrophage into a hyperinflammatory status.

Authors:  Jingfeng Tong; Lu Meng; Cheng Bei; Qingyun Liu; Min Wang; TingTing Yang; Howard E Takiff; Shuye Zhang; Qian Gao; Chuan Wang; Bo Yan
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 7.163

Review 7.  Crosstalk Between Liver Macrophages and Surrounding Cells in Nonalcoholic Steatohepatitis.

Authors:  Haiou Li; Yunjiao Zhou; Haizhou Wang; Meng Zhang; Peishan Qiu; Mengna Zhang; Ruike Zhang; Qiu Zhao; Jing Liu
Journal:  Front Immunol       Date:  2020-06-24       Impact factor: 7.561

Review 8.  Targeting phosphatidylserine for Cancer therapy: prospects and challenges.

Authors:  Wenguang Chang; Hongge Fa; Dandan Xiao; Jianxun Wang
Journal:  Theranostics       Date:  2020-07-23       Impact factor: 11.556

Review 9.  Contribution of Macrophage Efferocytosis to Liver Homeostasis and Disease.

Authors:  Andrea Kristina Horst; Gisa Tiegs; Linda Diehl
Journal:  Front Immunol       Date:  2019-11-14       Impact factor: 7.561

Review 10.  Hepatic Macrophage as a Key Player in Fatty Liver Disease.

Authors:  Liyun Xu; Wen Liu; Fuxiang Bai; Yong Xu; Xiaohong Liang; Chunhong Ma; Lifen Gao
Journal:  Front Immunol       Date:  2021-12-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.